Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines

Cancer Immunology, Immunotherapy

Volumn 61, Issue 6, 2012, Pages 827-838

  Poschke, I ^a   Mao, Y ^a   Adamson, L ^a   Salazar Onfray, F ^b   Masucci, G ^a   Kiessling, R ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

Cancer; Dendritic cells; MDSC; Melanoma; Vaccination

Indexed keywords

ANTIGEN; CD14 ANTIGEN; CYTOKINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; HLA DR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ANTIGEN PRESENTATION; ARTICLE; BONE MARROW CELL; CANCER IMMUNIZATION; CANCER PATIENT; CELL ISOLATION; CELL MATURATION; CELL MIGRATION; CELL VIABILITY; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG QUALITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MALE; MELANOMA; MONOCYTE; MYELOID DERIVED SUPPRESSOR CELL; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PURIFICATION; SUPPRESSOR CELL;

ADULT; AGED; ANTIGENS, CD14; CANCER VACCINES; COCULTURE TECHNIQUES; CYTOKINES; DENDRITIC CELLS; FEMALE; HLA-DR ANTIGENS; HUMANS; MALE; MELANOMA; MIDDLE AGED; MYELOID CELLS; NEOPLASM STAGING; OXIDATIVE STRESS;

EID: 84862330080     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1143-y     Document Type: Article

References (31)

1. Youn JI, Gabrilovich DI (2010) The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 40(11):2969-2975. doi:10.1002/eji.201040895
2. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, Bronte V (2010) Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 22(2):238-244. doi:10.1016/j.coi.2010.01.021
3. Cuenca AG, Delano MJ, Kelly-Scumpia KM, Moreno C, Scumpia PO, Laface DM, Heyworth PG, Efron PA, Moldawer LL (2011) A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol Med 17(3-4):281-292. doi:10.2119/molmed.2010.00178
4. Delano MJ, Scumpia PO, Weinstein JS, Coco D, Nagaraj S, Kelly-Scumpia KM, O'Malley KA, Wynn JL, Antonenko S, Al-Quran SZ, Swan R, Chung CS, Atkinson MA, Ramphal R, Gabrilovich DI, Reeves WH, Ayala A, Phillips J, Laface D, Heyworth PG, Clare-Salzler M, Moldawer LL (2007) MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med 204(6):1463-1474. doi:10.1084/jem.20062602 (Pubitemid 46919883)
5. Greifenberg V, Ribechini E, Rossner S, Lutz MB (2009) Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur J Immunol 39(10):2865-2876. doi:10.1002/eji.200939486
6. Brimnes MK, Vangsted AJ, Knudsen LM, Gimsing P, Gang AO, Johnsen HE, Svane IM (2010) Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol 72(6):540-547. doi:10.1111/j.1365-3083.2010.02463.x
7. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L (2007) Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25(18):2546-2553. doi:10.1200/JCO.2006.08.5829 (Pubitemid 47041228)
8. Gustafson MP, Lin Y, New KC, Bulur PA, O'Neill BP, Gastineau DA, Dietz AB (2010) Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol. doi:10.1093/neuonc/noq001
9. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP, Greten TF, Korangy F (2008) A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 135(1):234-243. doi:10.1053/j.gastro.2008.03.020 (Pubitemid 351899008)
10. Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB (2011) Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood 117(3):872-881. doi:10.1182/blood-2010-05-283820
11. Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, Lush RM, Antonia S, Gabrilovich DI (2006) All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 66(18):9299-9307. doi:10.1158/0008-5472.CAN-06-1690 (Pubitemid 44521152)
12. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R (2010) Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 70(11):4335-4345. doi:10.1158/0008-5472.CAN-09-3767
13. Schmielau J, Finn OJ (2001) Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 61(12):4756-4760 (Pubitemid 32691887)
14. Vuk-Pavlovic S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, Dietz AB (2010) Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate 70(4):443-455. doi:10.1002/pros.21078
15. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, Ortiz M, Nacken W, Sorg C, Vogl T, Roth J, Gabrilovich DI (2008) Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 205(10):2235-2249. doi:10.1084/jem.20080132
16. Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, Gabrilovich D (2003) All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 63(15):4441-4449 (Pubitemid 36951016)
17. Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kubler H, Yancey D, Dahm P, Vieweg J (2008) Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 14(24):8270-8278. doi:10.1158/1078-0432.CCR-08-0165
18. Schuler G (2010) Dendritic cells in cancer immunotherapy. Eur J Immunol 40(8):2123-2130. doi:10.1002/eji.201040630
19. Dietz AB, Padley DJ, Butler GW, Maas ML, Greiner CW, Gastineau DA, Vuk-Pavlovic S (2004) Clinical-grade manufacturing of DC from CD14+ precursors: experience from phase I clinical trials in CML and malignant melanoma. Cytotherapy 6(6):563-570 (Pubitemid 40028915)
20. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411-422. doi:10.1056/NEJMoa1001294
21. Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G, Gaudernack G (2011) hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunol Immunother 60(6):809-818. doi:10.1007/s00262-011-0991-9
22. Aguilera R, Saffie C, Tittarelli A, Gonzalez FE, Ramirez M, Reyes D, Pereda C, Hevia D, Garcia T, Salazar L, Ferreira A, Hermoso M, Mendoza-Naranjo A, Ferrada C, Garrido P, Lopez MN, Salazar-Onfray F (2011) Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells. Clin Cancer Res 17(8):2474-2483. doi:10.1158/1078-0432.CCR-10-2384
23. Lopez MN, Pereda C, Segal G, Munoz L, Aguilera R, Gonzalez FE, Escobar A, Ginesta A, Reyes D, Gonzalez R, Mendoza-Naranjo A, Larrondo M, Compan A, Ferrada C, Salazar-Onfray F (2009) Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J Clin Oncol 27(6):945-952. doi:10.1200/JCO.2008.18.0794
24. Wang S, Hong S, Yang J, Qian J, Zhang X, Shpall E, Kwak LW, Yi Q (2006) Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood 108(13):4071-4077. doi:10.1182/blood-2006-04-016980 (Pubitemid 44913277)
25. Breloer M, Fleischer B (2008) CD83 regulates lymphocyte maturation, activation and homeostasis. Trends Immunol 29(4):186-194. doi:10.1016/j.it.2008. 01.009
26. Tschoep K, Manning TC, Harlin H, George C, Johnson M, Gajewski TF (2003) Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccines. J Leukoc Biol 74(1):69-80 (Pubitemid 38040438)
27. Dieckmann D, Schultz ES, Ring B, Chames P, Held G, Hoogenboom HR, Schuler G (2005) Optimizing the exogenous antigen loading of monocyte-derived dendritic cells. Int Immunol 17(5):621-635. doi:10.1093/intimm/dxh243 (Pubitemid 41417860)
28. de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG, Punt CJ (2003) Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 9(14):5091-5100 (Pubitemid 37413557)
29. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R, Finke JH (2009) Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15(6):2148-2157. doi:10.1158/1078-0432.CCR- 08-1332
30. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, Dolcetti L, Bronte V, Borrello I (2006) Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 203(12):2691-2702. doi:10.1084/jem.20061104 (Pubitemid 44833345)
31. Nagaraj S, Youn JI, Weber H, Iclozan C, Lu L, Cotter MJ, Meyer C, Becerra CR, Fishman M, Antonia S, Sporn MB, Liby KT, Rawal B, Lee JH, Gabrilovich DI (2010) Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res 16(6):1812-1823. doi:10.1158/1078-0432.CCR-09-3272